Endocrine Abstracts

Background: Octreotide LAR is used in the treatment of Acromegaly and is effective in reducing growth hormone levels in the majority of patients. With the introduction of the Endocrine Specialist Nurse it has been possible to take their care into the community.
Method: A questionnaire was administered for both patients and practice nurses, to enable us to highlight the benefits and identify any problems. It was sent to 27 patients who receive Octreotide LAR and 27 GP Surgeries. The 27 patients had been receiving LAR for a period of between 6 months to 5 years. In the 27 GP Surgeries 1-4 nurses administered the injections.
Results: 23 patients and 22 practice nurses returned the questionnaire ( 85% and 81% respectively ). 23 patients received 505 injections over a period between 6 months to 5 years. 16 nurses, 72% reported needle blockage, occurring between 1-6 times. Of these there were no completely failed injections. Advising the use of a large 19g white needle eliminated the problem entirely and from October 2002 the company who manufacture LAR have incorporated larger bore needles within the injection pack. 21% of patients experienced problems for a few days following the injection including tenderness, bruising and aching at the injection site. However, all 23 patients were happy with their treatment and its overall effect.
Conclusion: Domicillary administration of Octreotide LAR provides an effective, convenient method of delivery, with a low complication rate and a high level of compliance.